GlaxoSmithKline isn't just going to sit back and let Cipla's generic stomp all over asthma blockbuster Advair--known as Seretide outside the U.S.--in India. It's turning to a strategy it's used elsewhere to help its aging med compete, and that's price-cutting.
GlaxoSmithKline joins other multinational pharma that witnessed a slowdown in China in the second quarter as heard on the July 29 earning call, with CEO Andrew Witty sounding in fine form, handling many of the questions directly.
GlaxoSmithKline, which has been laying off hundreds of employees in the face of falling Advair sales, is adding up to 140 employees at a facility in North Carolina. But it is a bittersweet turn of events since as many as 200 former GSK workers in the area who moved to jobs with CRO Parexel are getting their pink slips.
Eight months after the ax dropped late last year, 125 former GlaxoSmithKline staffers in Research Triangle Park found their jobs back on the chopping block Thursday as their new employer at Parexel included them in a lineup of new layoffs.
When GlaxoSmithKline reported last December that it was ripping into its R&D operations in Research Triangle Park, NC, and laying off 900 staffers, the pharma giant softened the blow by noting that some 450 of the workers would be transferring to Parexel, a major CRO with close ties to Glaxo. But today many of those jobs appear to be in danger after all.
GlaxoSmithKline CEO Andrew Witty had some upbeat Q2 revenue numbers to report, but a renewed effort to spur some enthusiasm for its drug pipeline fell flat with analysts.
GlaxoSmithKline is knee-deep in bribery allegations around the world, with accusations surfacing everywhere from Poland to the Middle East that the company engaged in wrongdoing. Now the drugmaker faces new claims in Romania, almost a year after it paid a pretty penny to resolve bribery charges in China.
GlaxoSmithKline's malaria jab got the green light from the EMA on Friday and the British pharma is making plans for a gradual rollout of the vaccine.
AstraZeneca and GlaxoSmithKline have secured direct connections to researchers at the University of Cambridge and its associated academic institutions. The arrangement is part of a "matchmaking" scheme, in which drugmakers will provide academics with funding for collaborative research and access to their experimental therapies.
On Wednesday, GlaxoSmithKline announced results for its first full quarter after closing its blockbuster asset swap with Novartis. And so far, things look "unremarkable."